IBONYSEPharmaceutical PreparationsFiscal year ends December 31

IMPACT BIOMEDICAL INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$3.06+0.38 (+14.18%)

Close on Oct 19, 2026

Market cap: $329.93M
P/E (TTM): –
Dividend yield: –

IMPACT BIOMEDICAL INC. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Depreciation & Amortization	1.15	1.12	1.12	1.11
Stock-Based Compensation	0.01	0.02	–	–
Deferred Income Taxes	-2.58	0.03	–	-0.62
Change in Accounts Receivable	0.00	0.13	–	–
Change in Inventory	0.01	–	–	–
Change in Accounts Payable	0.47	-0.44	0.29	0.42
Operating Cash Flow	-1.89	-2.85	-2.85	-2.24
Investing Cash Flow	0.00	0.00	-0.02	-0.35
Stock Issued	–	3.73	–	–
Debt Issued	–	1.12	2.87	–
Financing Cash Flow	-0.11	4.85	2.87	2.55
Net Change in Cash	-2.00	2.00	0.00	-0.04

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -1120.0%
Operating margin: -14597.1%
Net margin: 2254.3%
Return on equity, FY2025: -142.9%

Financial strength

Current ratio: 0.16
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.5%

Valuation

P/E ratio: –
Price to sales: 9426.66
Price to book: 30.65
Dividend yield: –